Daniel McQuaid
MD/PhD StudentAbout
Research
Publications
2026
Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas
Ruiz C, Ge X, McDonnell R, Agabiti S, McQuaid D, Tang A, Kharwa M, Goodell J, del M. Saavedra-Peña R, Wing A, Li G, Medici N, Robert M, Varshney R, Rudolph M, Gorelick F, Wysolmerski J, Canals D, Haley J, Rodeheffer M, Muzumdar M. Diet-induced phospholipid remodeling dictates ferroptosis sensitivity and tumorigenesis in the pancreas. Cancer Discovery 2026, 10.1158/2159-8290.cd-25-0734. PMID: 42053430, PMCID: PMC13227558, DOI: 10.1158/2159-8290.cd-25-0734.Peer-Reviewed Original ResearchThis study investigates how dietary fat composition influences pancreatic cancer, showing that monounsaturated fats promote tumor growth while polyunsaturated fats reduce risk by enhancing ferroptosis sensitivity.Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development
Garcia CC, Venkat A, McQuaid DC, Agabiti SS, Tong A, Mathew B, Cardone RL, Starble R, Ruiz CF, Zheng C, Sogunro A, Jacox JB, Loh KH, Kibbey RG, Krishnaswamy S, Muzumdar MD. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development. Nature Communications 2026 DOI: 10.1038/s41467-026-69821-2.Peer-Reviewed Original ResearchBeta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development
Garcia C, Venkat A, McQuaid D, Agabiti S, Tong A, Mathew B, Cardone R, Starble R, Ruiz C, Zheng C, Sogunro A, Jacox J, Loh K, Kibbey R, Krishnaswamy S, Muzumdar M. Beta cell-derived cholecystokinin drives obesity-associated pancreatic adenocarcinoma development. Nature Communications 2026, 17: 3292. PMID: 41760660, PMCID: PMC13066563, DOI: 10.1038/s41467-026-69821-2.Peer-Reviewed Original ResearchThis study investigates how obesity-induced cholecystokinin (CCK) expression in pancreatic beta cells drives pancreatic cancer development by altering cellular signaling within the environment of arising tumors, suggesting potential therapeutic targets.
2025
Direct genetic transformation bypasses tumor-associated DNA methylation alterations
Hetzel S, Hodis E, Torlai Triglia E, Kovacsovics A, Steinmann K, Gnirke A, Cui M, McQuaid D, Weigert R, Pohl G, Muzumdar M, Leyvraz S, Keilholz U, Yaspo M, Regev A, Kretzmer H, Smith Z, Meissner A. Direct genetic transformation bypasses tumor-associated DNA methylation alterations. Genome Biology 2025, 26: 212. PMID: 40676699, PMCID: PMC12273271, DOI: 10.1186/s13059-025-03650-2.Peer-Reviewed Original Research
2023
Physical Restraints in Advanced Illness #462
McQuaid D, Roberts A, Lescott S, Prsic E. Physical Restraints in Advanced Illness #462. Journal Of Palliative Medicine 2023, 26: 1150-1152. PMCID: PMC13175317, DOI: 10.1089/jpm.2023.0174.Peer-Reviewed Original Research
2022
IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original ResearchGlobal assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original Research
2018
Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
McClinch K, Avelar R, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky D, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan D, Plymate S, Sprenger C, Oh W, Levine A, Kirschenbaum A, Sfakianos J, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky M. Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer. Cancer Research 2018, 78: canres.0123.2017. PMID: 29358171, PMCID: PMC5899650, DOI: 10.1158/0008-5472.can-17-0123.Peer-Reviewed Original Research
2017
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem GM, Smith BE, Lai AC, Jaime-Figueroa S, McQuaid DC, Bondeson DP, Toure M, Dong H, Qian Y, Wang J, Crew AP, Hines J, Crews CM. The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study. Cell Chemical Biology 2017, 25: 67-77.e3. PMID: 29129716, PMCID: PMC5831399, DOI: 10.1016/j.chembiol.2017.09.009.Peer-Reviewed Original ResearchActivation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky D, Zaware N, Izadmehr S, Mazhar S, Wiredja D, O’Connor C, Hoon D, Dhawan N, Schlatzer D, Yao S, Leonard D, Borczuk A, Gokulrangan G, Wang L, Svenson E, Farrington C, Yuan E, Avelar R, Stachnik A, Smith B, Gidwani V, Giannini H, McQuaid D, McClinch K, Wang Z, Levine A, Sears R, Chen E, Duan Q, Datt M, Haider S, Ma’ayan A, DiFeo A, Sharma N, Galsky M, Brautigan D, Ioannou Y, Xu W, Chance M, Ohlmeyer M, Narla G. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. Journal Of Clinical Investigation 2017, 127: 2081-2090. PMID: 28504649, PMCID: PMC5451217, DOI: 10.1172/jci89548.Peer-Reviewed Original ResearchAnimalsAntineoplastic AgentsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmEnzyme ActivationEnzyme ActivatorsHumansMaleMice, Inbred BALB CMice, NudeMice, TransgenicProtein BindingProtein Phosphatase 2Proto-Oncogene Proteins p21(ras)Signal TransductionTumor BurdenXenograft Model Antitumor Assays